Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
887 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,851 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05139134 | Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma | unknown | — | 50 | Sohag UniversityOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04839029 | Bipolar Versus Mono-polar Needlescopic En Bloc TUR-BT | unknown | N/A | 200 | Benha UniversityOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors |
| unknown |
| Phase 2 |
| 265 |
| Jiangsu HengRui Medicine Co., Ltd.INDUSTRY |
| 1 |
| Jul 1, 2022 |
| clinicaltrials |
| NCT05392634 | Multicentral Preventive Antibiotics With Cystectomy Within Enhanced Recovery After Surgery(MACS) | unknown | Phase 3 | 98 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT04235556 | Integrated Care Pathway in Oncology (PASSION)(PASSION) | unknown | — | 1,800 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT05372302 | Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE)(CICERONE) | unknown | — | 100 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT04718948 | Multimodal Spectroscopy to Detect Urothelial Cancer in Urine | unknown | — | 500 | University of FlorenceOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT04770974 | Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic | unknown | — | 200 | University of FlorenceOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05154474 | Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy(SPACE2) | unknown | — | 150 | WepromOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT05344937 | Validation Study of Uromonitor in High Risk Microhematuria Patients | unknown | — | 343 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT02849535 | Impact of the PRISM-care Multidisciplinary Oncology Program on Secured Drug Intake of Patients With Kidney Cancer(PRISM care) | unknown | N/A | 190 | Hospices Civils de LyonOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03062059 | The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence | unknown | Phase 2 | 134 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04339933 | Detection of FGFR Gene Mutations in the Tumor Tissue and Urine of Patients With Urothelial Carcinoma | unknown | — | 92 | Ho Kyung SeoOTHER_GOV | 0 | Apr 7, 2022 | clinicaltrials |
| NCT04876313 | An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)(NURE-Combo) | unknown | Phase 2 | 29 | IRCCS San RaffaeleOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT04602702 | Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors(PDXovo) | unknown | — | 50 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT03759496 | Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer | unknown | Phase 2 | 39 | Hellenic GenitoUrinary Cancer GroupOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT03993249 | Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy | unknown | Phase 2 | 78 | Hellenic GenitoUrinary Cancer GroupOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT05077852 | Intravesical Prostatic Protrusion Mimicking Urothelial Cell Carcinoma of the Bladder | unknown | — | 194 | Ankara Training and Research HospitalOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT02994758 | Development of Diagnostics and Treatment of Urological Cancers(DEDUCER) | unknown | N/A | 100 | Helsinki University Central HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT03762161 | A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer | unknown | Phase 2 | 22 | Rahul ParikhOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02535650 | Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma | unknown | Phase 2 | 19 | Samsung Medical CenterOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05262166 | Opioid Free Anesthesia in Prolonged Surgery | unknown | N/A | 34 | Mansoura UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05262413 | A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) | unknown | Phase 1 / Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 2, 2022 | clinicaltrials |
| NCT03177239 | Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)(UNISoN) | unknown | Phase 2 | 85 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT05235607 | Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors | unknown | Phase 1 | 60 | Sichuan UniversityOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT05220124 | A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma | unknown | Phase 4 | 190 | Tianjin Medical University Second HospitalOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study(YSCH-01) | unknown | Early Phase 1 | 28 | Shanghai Fengxian District Central HospitalOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT04603846 | A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma | unknown | Phase 1 | 20 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Jan 24, 2022 | clinicaltrials |
| NCT02992990 | Bladder Tumor Biopsy Study to Improve Preoperative Determination of Stage and Grade | unknown | N/A | 30 | Baylor College of MedicineOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT05108077 | Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells | unknown | Phase 1 / Phase 2 | 20 | Institute of Biophysics and Cell Engineering of National Academy of Sciences of BelarusOTHER_GOV | 1 | Jan 14, 2022 | clinicaltrials |
| NCT03715985 | Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)(NeoPepVac) | unknown | Phase 1 / Phase 2 | 12 | Herlev HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05146635 | Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled Trial | unknown | N/A | 110 | Mansoura UniversityOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04946266 | Prospective Validation of the Prognostic Value of Long Non-coding MFI2-AS1 RNA in Localized Clear Cell Kidney Cancers(MFI2-PREDICT) | unknown | — | 260 | University Hospital, Strasbourg, FranceOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT05170555 | Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617 | unknown | N/A | 40 | Peking Union Medical College HospitalOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05167916 | Can Four Weeks-check Cystoscopy and Urine Cytology After Primary Complete Resection of T1 Bladder Cancer Replace Repeat Biopsy? | unknown | N/A | 200 | Mansoura UniversityOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT01141816 | Contrast-enhanced Ultrasound for Follow-up After Radiofrequency Ablation of Kidney Lesions | unknown | N/A | 30 | St. Joseph's Healthcare HamiltonOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT05160285 | Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma | unknown | Phase 2 | 29 | YULISUOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT04839510 | A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer | unknown | Phase 2 | 58 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 14, 2021 | clinicaltrials |
| NCT05148728 | Active Surveillance vs in Office Fulguration for Low Grade Bladder Cancer Tumors | unknown | N/A | 120 | Vall Hebron Insitut RecercaNETWORK | 1 | Dec 8, 2021 | clinicaltrials |
| NCT02689167 | Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma(SURF) | unknown | Phase 2 | 226 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Nov 29, 2021 | clinicaltrials |
| NCT05135832 | Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma(PRORECECA) | unknown | N/A | 174 | Herlev and Gentofte HospitalOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT05124431 | Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma(ALTER-UC-001) | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT05123404 | Validation of VI-RADS for the Detection of Detrusor Muscle Invasion | unknown | N/A | 60 | Egyptian Biomedical Research NetworkNETWORK | 1 | Nov 17, 2021 | clinicaltrials |
| NCT05112523 | The Performance of Cancer Risk Genes in the Necessity of Secondary TURBT(RE-TURBT) | unknown | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 9, 2021 | clinicaltrials |
| NCT05109182 | Virtual 3D Modelling for Improved Surgical Planning of Robotic-assisted Partial Nephrectomy(VISP) | unknown | N/A | 328 | Innersight Labs LtdINDUSTRY | 0 | Nov 5, 2021 | clinicaltrials |
| NCT04730232 | Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable | unknown | Phase 2 | 63 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT05097404 | Clinical Utility of VI-RADS in Diagnosis of MIBC | unknown | — | 73 | Samsung Medical CenterOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT05096533 | The Application Value of Artificial Intelligence in MRI Precision Diagnosis and Treatment of Bladder Cancer | unknown | — | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT05086666 | A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 | unknown | Phase 1 / Phase 2 | 108 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Oct 21, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jul 29, 2022source: clinicaltrials